{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:08:34Z","timestamp":1776679714285,"version":"3.51.2"},"reference-count":63,"publisher":"Wiley","issue":"S6","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Obwohl bislang f\u00fcr die Rosazea keine kurative Therapie besteht, k\u00f6nnen verschiedene Optionen zur Behandlung der Symptome und zur Vorbeugung von Exazerbationen empfohlen werden. Neben Selbsthilfema\u00dfnahme wie der Vermeidung von Triggerfaktoren und einer geeigneten Hautpflege sollte das Rosazea\u2010Management bei Patienten mit erythemat\u00f6ser und leichter bis schwerer papulopustul\u00f6ser Rosazea die Anwendung topischer Pr\u00e4parate als First\u2010Line\u2010Therapie umfassen. Da \u00dcberlappungen der charakteristischen Rosazea\u2010Symptome im klinischen Alltag die Regel sind, sollte die medikament\u00f6se Therapie auf die individuellen Symptome zugeschnitten werden; auch eine Kombinationstherapie kann erforderlich sein. Zu den f\u00fcr die Behandlung der Hauptsymptome der Rosazea zugelassenen Wirkstoffen geh\u00f6ren Brimonidin gegen das Erythem sowie Ivermectin, Metronidazol oder Azelains\u00e4ure gegen entz\u00fcndliche L\u00e4sionen. Ihre Wirksamkeit wurde in zahlreichen validen, gut kontrollierten Studien belegt. Dar\u00fcber hinaus existieren verschiedene nicht zugelassene topische Behandlungsm\u00f6glichkeiten, deren Wirksamkeit und Sicherheit noch in gr\u00f6\u00dferen, kontrollierten Studien zu untersuchen ist.<\/jats:p>","DOI":"10.1111\/ddg.13143_g","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T12:55:39Z","timestamp":1479732939000},"page":"17-28","source":"Crossref","is-referenced-by-count":1,"title":["Rosazea\u2010Management: Update \u00fcber allgemeine Ma\u00dfnahmen und topische Therapieoptionen"],"prefix":"10.1111","volume":"14","author":[{"given":"M","family":"Schaller","sequence":"first","affiliation":[{"name":"Universit\u00e4ts\u2010Hautklinik Klinikum der Universit\u00e4t T\u00fcbingen Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Sch\u00f6fer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Dermatologie, Venerologie und Allergologie Johann Wolfgang Goethe\u2010Universit\u00e4t Frankfurt\/Main Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Homey","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Dermatologie Universit\u00e4tsklinikum D\u00fcsseldorf Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Dermatologie und Allergologie Charit\u00e9 \u2010 Universit\u00e4tsmedizin Berlin Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Gieler","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Psychosomatische Medizin, Psychosomatische Dermatologie Universit\u00e4tsklinikum Gie\u00dfen Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Dermatologie, Allergologie und Dermatochirurgie Helios Kliniken Wuppertal, Universit\u00e4t Witten\/Herdecke Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TA","family":"Luger","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Hautkrankheiten, Allgemeine Dermatologie und Venerologie Universit\u00e4tsklinikum M\u00fcnster Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ruzicka","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Dermatologie und Allergologie Ludwig\u2010Maximilians\u2010Universit\u00e4t M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Steinhoff","sequence":"additional","affiliation":[{"name":"Department of Dermatology and UCD Charles Institute for Translational Dermatology University Collge Dublin Dublin Irland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"e_1_2_19_2_1","first-page":"234","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care","volume":"92","author":"Del Rosso JQ","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_19_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048"},{"key":"e_1_2_19_4_1","first-page":"159","article-title":"Update on the management of rosacea","volume":"8","author":"Weinkle AP","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"e_1_2_19_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.045"},{"key":"e_1_2_19_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12101_suppl"},{"key":"e_1_2_19_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.027"},{"key":"e_1_2_19_8_1","doi-asserted-by":"crossref","unstructured":"ReinholzM RuzickaT SteinhoffMet\u00a0al.Pathogenesis and clinical presentation of rosacea as a key for a symptom\u2010oriented therapy. J Dtsch Dermatol Ges 2016; 14(Suppl 6):4\u201316.","DOI":"10.1111\/ddg.13139"},{"key":"e_1_2_19_9_1","first-page":"16","article-title":"Korneotherapeutische Hautpflege bei Rosacea","volume":"3","author":"Lautenschl\u00e4ger H","year":"2010","journal-title":"Aesthetische Dermatologie"},{"key":"e_1_2_19_10_1","first-page":"26","article-title":"Rosacea, Reactive Oxygen Species, and Azelaic Acid","volume":"2","author":"Jones D","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_19_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-013-0394-4"},{"key":"e_1_2_19_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1312933110"},{"key":"e_1_2_19_13_1","first-page":"277","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents","volume":"92","author":"Del Rosso JQ","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_19_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003262.pub5"},{"key":"e_1_2_19_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03751.x"},{"key":"e_1_2_19_16_1","doi-asserted-by":"crossref","unstructured":"SchallerM Sch\u00f6ferH HomeyBet\u00a0al.State of the art: Systemic rosacea management. J Dtsch Dermatol Ges 2016; 14(Suppl 6):29\u201337.","DOI":"10.1111\/ddg.13141"},{"key":"e_1_2_19_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10716.x"},{"key":"e_1_2_19_18_1","first-page":"650","article-title":"Efficacy and safety of once\u2010daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double\u2010blind, and vehicle\u2010controlled pivotal studies","volume":"12","author":"Fowler J","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_19_1","first-page":"56","article-title":"Long\u2010term safety and efficacy of once\u2010daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of a 1\u2010year open\u2010label study","volume":"13","author":"Moore A","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.04.002"},{"key":"e_1_2_19_21_1","first-page":"33","article-title":"Optimizing the use of topical brimonidine in rosacea management: panel recommendations","volume":"14","author":"Tanghetti EA","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.036"},{"key":"e_1_2_19_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.010"},{"key":"e_1_2_19_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13305"},{"key":"e_1_2_19_25_1","first-page":"316","article-title":"Efficacy and safety of ivermectin 1 % cream in treatment of papulopustular rosacea: results of two randomized, double\u2010blind, vehicle\u2010controlled pivotal studies","volume":"13","author":"Stein Gold L","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00684.x"},{"key":"e_1_2_19_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00403-4"},{"key":"e_1_2_19_28_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0022-3565(24)35272-3","article-title":"Anti\u2010 inflammatory activity of macrolide antibiotics","volume":"292","author":"Ianaro A","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_19_29_1","first-page":"1380","article-title":"Ivermectin Phase 3 Study Group. Long\u2010term safety of ivermectin 1 % cream vs azelaic acid 15 % gel in treating inflammatory lesions of rosacea: results of two 40\u2010week controlled, investigator\u2010blinded trials","volume":"13","author":"Stein Gold L","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13408"},{"key":"e_1_2_19_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13537"},{"key":"e_1_2_19_32_1","first-page":"317","article-title":"Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter","volume":"5","author":"Yoo J","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70085-X"},{"issue":"4","key":"e_1_2_19_34_1","first-page":"3","article-title":"Efficacy and safety of once\u2010daily metronidazole 1 % gel compared with twice\u2010daily azelaic acid 15 % gel in the treatment of rosacea","volume":"77","author":"Wolf JE","year":"2006","journal-title":"Cutis"},{"key":"e_1_2_19_35_1","first-page":"101","article-title":"Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid","volume":"13","author":"Del Rosso JQ","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_36_1","first-page":"306","article-title":"Azelaic acid foam 15 % in the treatment of papulopustular rosacea: a randomized, double\u2010blind, vehicle\u2010controlled study","volume":"92","author":"Draelos ZD","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_19_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2005.02769.x"},{"key":"e_1_2_19_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07466.x"},{"key":"e_1_2_19_39_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.308"},{"key":"e_1_2_19_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/000155599750009906"},{"key":"e_1_2_19_41_1","first-page":"177","article-title":"A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea","volume":"56","author":"Signore R","year":"1995","journal-title":"Cutis"},{"key":"e_1_2_19_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065849"},{"key":"e_1_2_19_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2009.09.006"},{"key":"e_1_2_19_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02125.x"},{"key":"e_1_2_19_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.03.033"},{"key":"e_1_2_19_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03167.x"},{"key":"e_1_2_19_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02130.x"},{"key":"e_1_2_19_48_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051380"},{"key":"e_1_2_19_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01223.x"},{"key":"e_1_2_19_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02157-1"},{"key":"e_1_2_19_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03427.x"},{"key":"e_1_2_19_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02589.x"},{"key":"e_1_2_19_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07669.x"},{"key":"e_1_2_19_54_1","doi-asserted-by":"crossref","first-page":"pii","DOI":"10.5070\/D3215027532","article-title":"Rosacea\u2010like eruption due to topical pimecrolimus","volume":"21","author":"El\u2010Heis S","year":"2015","journal-title":"Dermatol online J"},{"key":"e_1_2_19_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.6.679"},{"key":"e_1_2_19_56_1","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15 % gel in combination with oral doxycycline as initial therapy and azelaic acid 15 % gel as maintenance monotherapy","volume":"8","author":"Thiboutot DM","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12419"},{"key":"e_1_2_19_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0037-2"},{"issue":"3","key":"e_1_2_19_59_1","first-page":"544","article-title":"Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline","volume":"8","author":"Arman A","year":"2015","journal-title":"Int J Ophthalmol"},{"key":"e_1_2_19_60_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.22.47"},{"key":"e_1_2_19_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000176611.88579.0a"},{"key":"e_1_2_19_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181cda38f"},{"key":"e_1_2_19_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181ca38a0"},{"key":"e_1_2_19_64_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.801991"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13143_g","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13143_g","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.13143_g","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:42:51Z","timestamp":1749757371000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.13143_g"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":63,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/ddg.13143_g"],"URL":"https:\/\/doi.org\/10.1111\/ddg.13143_g","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}